logo
episode-header-image
Sep 2023
35m 38s

Why One Drug Company Held Back a Better ...

The New York Times
About this episode
For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents. Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and h ... Show More
Up next
Yesterday
Arizona’s Food Stamp Crisis Is Coming for the Rest of the U.S.
The United States is undergoing one of the biggest changes to its social safety net in recent history, with huge numbers of people getting dropped from the government’s food assistance program. Nowhere has this been more dramatic than in Arizona. Jason DeParle, who covers poverty ... Show More
31m 9s
Aug 4
Will Michigan Rewrite the Rules of Democratic Politics?
In Michigan, a race for U.S. Senate is not only testing the growing appeal of left-wing populism. It could also be a turning point in a long-running debate among Democratic voters about the importance of electability. Michael Kruse, who writes about politics for The New York Time ... Show More
40m 32s
Aug 3
The Tangled Tale of the Tate Brothers and the Trumps
Warning: This episode contains strong language. Over the past decade, the Tate brothers have built a global empire around pornography, hypermasculinity and overt misogyny. At the same time, they have been repeatedly accused of assaulting and trafficking women. A Times investigati ... Show More
39m 41s
Recommended Episodes
Jul 2022
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ... Show More
15m 33s
Jun 2020
Learning to Love Big Pharma
Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How ... Show More
13m 27s
Apr 2021
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ... Show More
12m 48s
Jul 2023
Sawbones: Patents vs. Life-Saving Drugs
<p>John Green recently made a video asking Johnson & Johnson not to extend their patent on a tuberculosis drug, which would keep it exclusive and expensive. Dr. Sydnee and Justin talk about how drug patents work, the recent (good) update about bedaquiline specifically, and the ne ... Show More
38m 46s
Jan 2020
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ... Show More
12m 36s
Oct 2021
Sick Money (Pt 1): Exposing the drug companies' price gouging tactics
In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More
29m 31s
Sep 2023
2. The drug behind Europe's most valuable company
How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discove ... Show More
56m 39s
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s